Nanomedicine Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Nanomedicine stocks.

Nanomedicine Stocks Recent News

Date Stock Title
Apr 30 AZN Novo, Teva, AstraZeneca issued FTC warnings over ‘bogus’ patents
Apr 30 AZN AstraZeneca PLC (NASDAQ:AZN) Q1 2024 Earnings Call Transcript
Apr 29 AZN AstraZeneca Admits Its COVID-19 Vaccine May Cause Blood Clotting Side Effect In Very Rare Case, But Causal Mechanism Unknown
Apr 29 AZN AstraZeneca’s Fasenra: Approval for asthma may initiate COPD approval
Apr 29 AZN AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement
Apr 29 AZN AstraZeneca's Enhertu buoyed by progression-free survival data in breast cancer
Apr 29 AZN AstraZeneca, Daiichi look to broaden Enhertu use again with new study data
Apr 29 AZN ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow
Apr 29 AZN Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
Apr 28 AZN J&J, Roche, AstraZeneca poised to have highest orphan drug sales by end of decade
Apr 27 NBTX Nanobiotix S.A. (NBTX) Q4 2023 Earnings Call Transcript
Apr 27 AZN AstraZeneca: A Triple Shot Of Income, Growth, And Value
Apr 27 AZN AstraZeneca PLC (LON:AZN) Beat Earnings, And Analysts Have Been Reviewing Their Forecasts
Apr 26 AZN Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
Apr 26 AZN AstraZeneca: Strong In A Weak Market
Apr 26 AZN Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect
Apr 26 AZN Top 4 Health Care Stocks That May Plunge This Month
Apr 25 AZN AstraZeneca CEO on US-China tensions: 'We have established a very resilient supply chain'
Apr 25 NBTX Nanobiotix reports FY results
Apr 25 AZN Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Nanomedicine

Nanomedicine is the medical application of nanotechnology. Nanomedicine ranges from the medical applications of nanomaterials and biological devices, to nanoelectronic biosensors, and even possible future applications of molecular nanotechnology such as biological machines. Current problems for nanomedicine involve understanding the issues related to toxicity and environmental impact of nanoscale materials (materials whose structure is on the scale of nanometers, i.e. billionths of a meter).Functionalities can be added to nanomaterials by interfacing them with biological molecules or structures. The size of nanomaterials is similar to that of most biological molecules and structures; therefore, nanomaterials can be useful for both in vivo and in vitro biomedical research and applications. Thus far, the integration of nanomaterials with biology has led to the development of diagnostic devices, contrast agents, analytical tools, physical therapy applications, and drug delivery vehicles.
Nanomedicine seeks to deliver a valuable set of research tools and clinically useful devices in the near future. The National Nanotechnology Initiative expects new commercial applications in the pharmaceutical industry that may include advanced drug delivery systems, new therapies, and in vivo imaging. Nanomedicine research is receiving funding from the US National Institutes of Health Common Fund program, supporting four nanomedicine development centers.Nanomedicine sales reached $16 billion in 2015, with a minimum of $3.8 billion in nanotechnology R&D being invested every year. Global funding for emerging nanotechnology increased by 45% per year in recent years, with product sales exceeding $1 trillion in 2013. As the nanomedicine industry continues to grow, it is expected to have a significant impact on the economy.

Browse All Tags